Oncolytic Herpes Simplex Virus Tumor Targeting and Neutralization Escape by Engineering Viral Envelope Glycoproteins

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2019 Feb 26

PMID 30799657

Citations 17

Authors

Xiao-Qin Liu

Hong-Yi Xin

Yan-Ning Lyu

Zhao-Wu Ma

Xiao-Chun Peng

Ying Xiang

Ying-Ying Wang

Zi-Jun Wu

Jun-Ting Cheng

Jia-Fu Ji

Ji-Xin Zhong

Bo-Xu Ren

Xian-Wang Wang

Hong-Wu Xin

Affiliations

Soon will be listed here.

Abstract

Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and some side effects. To overcome such challenges, here we review the genetic engineering of the envelope glycoproteins for oHSVs to target tumors specifically, and at the same time we summarize the many neutralization antibodies against the envelope glycoproteins and align the neutralization epitopes with functional domains of the respective glycoproteins for future identification of new functions of the glycoproteins and future engineering of the epitopes to escape from host neutralization.

Citing Articles

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.

Wang X, Shen Y, Wan X, Hu X, Cai W, Wu Z J Transl Med. 2023; 21(1):500.

PMID: 37491263 PMC: 10369732. DOI: 10.1186/s12967-023-04360-8.

Antiviral Effect of Polyphenolic Substances in against HSV-2 Infection Using and Approaches.

Zhang H, Li Z, Li C, Chen R, Liu T, Jiang Y Evid Based Complement Alternat Med. 2022; 2022:7953728.

PMID: 35646147 PMC: 9132656. DOI: 10.1155/2022/7953728.

The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach.

Forte I, Indovina P, Montagnaro S, Costa A, Iannuzzi C, Capone F Viruses. 2021; 13(12).

PMID: 34960727 PMC: 8703924. DOI: 10.3390/v13122458.

Multifunctional Non-Coding RNAs Mediate Latent Infection and Recurrence of Herpes Simplex Viruses.

Zhang Y, Zeng L, Wang J, Cai W, Cui W, Song T Infect Drug Resist. 2021; 14:5335-5349.

PMID: 34934329 PMC: 8684386. DOI: 10.2147/IDR.S334769.

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy.

Rahman M, McFadden G Cancers (Basel). 2021; 13(21).

PMID: 34771615 PMC: 8582515. DOI: 10.3390/cancers13215452.

References

Debinski W, Gibo D, Slagle B, Powers S, Gillespie G . Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol. 1999; 15(3):481-6. DOI: 10.3892/ijo.15.3.481. View

Krummenacher C, Rux A, Whitbeck J, Lou H, Baribaud I, Hou W . The first immunoglobulin-like domain of HveC is sufficient to bind herpes simplex virus gD with full affinity, while the third domain is involved in oligomerization of HveC. J Virol. 1999; 73(10):8127-37. PMC: 112829. DOI: 10.1128/JVI.73.10.8127-8137.1999. View

Shukla D, Liu J, Blaiklock P, Shworak N, Bai X, Esko J . A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell. 1999; 99(1):13-22. DOI: 10.1016/s0092-8674(00)80058-6. View

Whitbeck J, Muggeridge M, Rux A, Hou W, Krummenacher C, Lou H . The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain. J Virol. 1999; 73(12):9879-90. PMC: 113037. DOI: 10.1128/JVI.73.12.9879-9890.1999. View

Sanna P, Ramiro-Ibanez F, De Logu A . Synergistic interactions of antibodies in rate of virus neutralization. Virology. 2000; 270(2):386-96. DOI: 10.1006/viro.2000.0276. View

Markert J, Medlock M, Rabkin S, Gillespie G, Todo T, Hunter W . Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7(10):867-74. DOI: 10.1038/sj.gt.3301205. View

Muggeridge M . Characterization of cell-cell fusion mediated by herpes simplex virus 2 glycoproteins gB, gD, gH and gL in transfected cells. J Gen Virol. 2000; 81(Pt 8):2017-2027. DOI: 10.1099/0022-1317-81-8-2017. View

Kuan C, Wikstrand C, Archer G, Beers R, Pastan I, Zalutsky M . Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer. 2000; 88(6):962-9. DOI: 10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u. View

Todo T, Martuza R, Rabkin S, Johnson P . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001; 98(11):6396-401. PMC: 33479. DOI: 10.1073/pnas.101136398. View

10.

Lopez M, Cocchi F, Avitabile E, Leclerc A, Adelaide J, Dubreuil P . Novel, soluble isoform of the herpes simplex virus (HSV) receptor nectin1 (or PRR1-HIgR-HveC) modulates positively and negatively susceptibility to HSV infection. J Virol. 2001; 75(12):5684-91. PMC: 114282. DOI: 10.1128/JVI.75.12.5684-5691.2001. View

11.

Carfi A, Willis S, Whitbeck J, Krummenacher C, Cohen G, Eisenberg R . Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell. 2001; 8(1):169-79. DOI: 10.1016/s1097-2765(01)00298-2. View

12.

Johnson D, Huber M . Directed egress of animal viruses promotes cell-to-cell spread. J Virol. 2001; 76(1):1-8. PMC: 135733. DOI: 10.1128/jvi.76.1.1-8.2002. View

13.

Fu X, Zhang X . Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 2002; 62(8):2306-12. View

14.

Zhou G, Ye G, Debinski W, Roizman B . Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A. 2002; 99(23):15124-9. PMC: 137554. DOI: 10.1073/pnas.232588699. View

15.

Cairns T, Milne R, Ponce-de-Leon M, Tobin D, Cohen G, Eisenberg R . Structure-function analysis of herpes simplex virus type 1 gD and gH-gL: clues from gDgH chimeras. J Virol. 2003; 77(12):6731-42. PMC: 156167. DOI: 10.1128/jvi.77.12.6731-6742.2003. View

16.

Friedman H . Immune evasion by herpes simplex virus type 1, strategies for virus survival. Trans Am Clin Climatol Assoc. 2003; 114:103-12. PMC: 2194497. View

17.

Yoon M, Zago A, Shukla D, Spear P . Mutations in the N termini of herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion receptors HVEM, nectin-2, and 3-O-sulfated heparan sulfate but not with nectin-1. J Virol. 2003; 77(17):9221-31. PMC: 187404. DOI: 10.1128/jvi.77.17.9221-9231.2003. View

18.

Hutchinson L, Browne H, Wargent V, Davis-Poynter N, Primorac S, Goldsmith K . A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J Virol. 1992; 66(4):2240-50. PMC: 289017. DOI: 10.1128/JVI.66.4.2240-2250.1992. View

19.

Jogger C, Montgomery R, Spear P . Effects of linker-insertion mutations in herpes simplex virus 1 gD on glycoprotein-induced fusion with cells expressing HVEM or nectin-1. Virology. 2004; 318(1):318-26. DOI: 10.1016/j.virol.2003.10.004. View

20.

Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel D . HSV-1 virions engineered for specific binding to cell surface receptors. Mol Ther. 2004; 9(3):419-27. DOI: 10.1016/j.ymthe.2003.12.010. View